Latest Healthcare News

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Ryman Healthcare nearly doubles operating profitability and generates positive free cash flow for the first time in over a decade, while shifting strategy toward sustainable growth and targeting dividend returns by FY28.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

EBR Systems has secured a significant regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) initiates a National Coverage Determination (NCD) for its WiSE wireless cardiac pacing system, aiming for approval by early 2027.

Careteq Limited’s strategic investor Antanas Guoga has converted all his convertible notes into shares, wiping out the company’s convertible debt and simplifying its capital structure ahead of its AI healthtech growth push.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.

Promisia Healthcare reported a 58% jump in underlying EBITDAF to $6.6 million for FY26, driven by improved occupancy and operational upgrades. The company introduced a dividend policy tied to operating free cash flow, signalling confidence in sustained cash generation.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.